Publication in Journal of Clinical Oncology demonstrates that Oncotype DX predicts late distant recurrence in breast cancer | oncotest
News
News
oncotest > News > Publication in Journal of Clinical Oncology demonstrates that Oncotype DX predicts late distant recurrence in breast cancer

Updates > News

Publication in Journal of Clinical Oncology demonstrates that Oncotype DX predicts late distant recurrence in breast cancer

The Journal of Clinical Oncology, the official journal of the American Society of Clinical Oncology (ASCO), recently published results from a large study confirming the ability of Oncotype DX, in combination with quantitative estrogen-receptor (ER) expression, to accurately predict after five years of tamoxifen therapy the risk of late distant recurrence up to 15 years in patients with early-stage, hormone receptor-positive breast cancer. These findings suggest that the Oncotype DX test may help identify which patients are most likely to benefit from extended hormonal treatment with tamoxifen.

“Extending tamoxifen treatment for 10 years has been shown to be associated with better outcomes, but not all patients have the same risk of late distant recurrence – meaning cancer coming back after five years – and it is important to know a patient’s risk in order to better understand who will benefit the most from extended hormonal treatment,” said Norman Wolmark, M.D., chairman of the National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation, the organisation that carried out the study in conjunction with Genomic Health. “The results of this large study confirm that Oncotype DX helps better define who is at greatest risk of a late distant recurrence and who would likely derive the greatest benefit from extended tamoxifen therapy.”

About Oncotype DX

Oncotype DX is the only genomic test validated for its ability to predict the likelihood of chemotherapy benefit as well as risk of recurrence in early-stage breast cancer.

Healthcare systems across Europe are recognising the value of the test, which is incorporated in all major international clinical guidelines. Following assessment and recommendation by NICE in 2013, the Oncotype DX test is now widely available to patients across the UK. Other European countries that reimburse the test include Switzerland, Ireland, Greece and Spain. To learn more about the Oncotype DX test, visit: www.OncotypeDX.com

Contact Us